| Literature DB >> 35287625 |
Kyun Young Kim1, Jung-Hwa Ryu1, Duk-Hee Kang1, Seung-Jung Kim1, Kyu Bok Choi1, Shina Lee2.
Abstract
BACKGROUND: Early fluid management is considered a key element affecting mortality in critically ill patients requiring continuous renal replacement therapy (CRRT). Most studies have primarily focused on patients with intrinsic acute kidney injury requiring CRRT, although end-stage kidney disease (ESKD) patients generally exhibit greater vulnerability. We investigated the association between fluid balance and short-term mortality outcomes in ESKD patients undergoing chronic hemodialysis and requiring CRRT.Entities:
Keywords: Chronic hemodialysis; Continuous renal replacement therapy; Cumulative input; Cumulative output; Short-term mortality
Mesh:
Year: 2022 PMID: 35287625 PMCID: PMC8919557 DOI: 10.1186/s12882-022-02725-7
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Flow diagram for patient enrollment
Baseline Characteristics
| Survivor, | Non-survivor, | |||
|---|---|---|---|---|
| Demographics | ||||
| Age | 67.9 ± 11.4 | 67.8 ± 11.1 | 68.2 ± 12.1 | 0.86 |
| Male, | 71 (64.5) | 50 (65.8) | 21 (61.8) | 0.68 |
| Body weight at admission (Kg) | 60.9 ± 12.5 | 61.3 ± 11.8 | 59.8 ± 14.0 | 0.56 |
| BMI at admission (kg/m2) | 60.9 ± 12.5 | 23.4 ± 4.2 | 22.5 ± 4.0 | 0.31 |
| Comorbidities, | ||||
| Hypertension | 79 (71.8) | 58 (76.3) | 21(61.8) | 0.12 |
| Diabetes | 61 (55.5) | 47 (61.8) | 14(41.2) | 0.04 |
| CVDs | 46 (41.8) | 34 (44.7) | 12(35.3) | 0.35 |
| Malignancy | 19 (17.3) | 13 (17.1) | 6(17.6) | 0.94 |
| Cause of hospitalization, | ||||
| Sepsis | 83 (75.5) | 55 (72.4) | 28 (82.4) | 0.26 |
| non-sepsis | 27 (24.5) | 21 (27.6) | 6 (17.6) | |
| CCI | 6.7 ± 2.2 | 6.9 ± 2.3 | 6.3 ± 1.9 | 0.20 |
| SOFA | 11.3 ± 3.4 | 11.6 ± 3.6 | 10.6 ± 2.9 | 0.20 |
| GCS | 8.0 ± 4.0 | 8.6 ± 3.8 | 6.4 ± 4.0 | 0.01 |
| APACHE II | 22.4 ± 6.8 | 21.3 ± 6.6 | 24.7 ± 6.8 | 0.01 |
| Mechanical Ventilation, | 35 (31.8) | 24 (31.6) | 0.94 | |
Data were presented as mean ± standard deviation or number (%). Abbreviation: BMI Body mass index, CVD Cardiovascular disease, CCI Charlson Comorbidity Index, SOFA, Sequential Organ Failure Assessment, GCS Glasgow Coma Scale, APCHE II Acute Physiology and Chronic Health Evaluation II
Clinical and laboratory parameters at CRRT initiation
| Overall ( | ||||
|---|---|---|---|---|
| Survivor, | Non-survivor, | |||
| 115.5 ± 24.7 | 118.0 ± 25.9 | 110.0 ± 21.1 | ||
| 67.6 ± 14.5 | 68.5 ± 15.4 | 65.6 ± 12.1 | ||
| 83.6 ± 14.9 | 85.0 ± 15.2 | 80.4 ± 14.0 | ||
| 97.0 ± 23.4 | 94.5 ± 24.4 | 102.5 ± 20.2 | ||
| 58.0 (52.7) | 34 (44.7) | 24 (70.6) | ||
| | 6.1 ± 6.7 | 7.0 ± 7.5 | 4.1 ± 3.8 | |
| | 31.5 ± 47.6 | 37.2 ± 49.9 | 18.5 ± 39.8 | |
| | 1020.0 ± 206.8 | 1036.2 ± 171.8 | 983.8 ± 268.8 | |
| | 1170.9 ± 894.8 | 1225.7 ± 1058.7 | 1048.5 ± 273.7 | |
| | 119.5 ± 30.5 | 120.7 ± 31.6 | 116.8 ± 28.1 | |
| 60.0 (54.5) | 48 (64) | 12 (35.3) | |
| | 5.2 ± 2.2 | 5.22 ± 2.17 | 5.18 ± 2.27 | |
| | 13.3 ± 10.0 | 13.28 ± 10.78 | 13.19 ± 7.95 | |
| | 11.7 ± 7.5 | 11.31 ± 6.52 | 12.59 ± 9.51 | |
| | 9.2 ± 1.7 | 9.23 ± 1.59 | 9.03 ± 1.9 | |
| | 143.8 ± 84.9 | 142.8 ± 84.16 | 145.91 ± 87.63 | |
| | 2.2 ± 5.6 | 2.03 ± 5.76 | 2.61 ± 5.33 | |
| | 1.0 ± 1.1 | 0.91 ± 1.03 | 1.13 ± 1.11 | |
| | 183.5 ± 918.1 | 168.33 ± 1024.15 | 217.56 ± 631.24 | |
| | 99.1 ± 471.5 | 95.54 ± 545.4 | 106.79 ± 250.34 | |
| | 32.2 ± 39.5 | 26.1 ± 29.85 | 44.62 ± 52.88 | |
| | 7.4 ± 0.1 | 7.37 ± 0.09 | 7.38 ± 0.11 | |
| | -2.8 ± 6.3 | -2.74 ± 6.26 | -2.84 ± 6.54 | |
| | 104.4 ± 57.9 | 105.21 ± 53.39 | 102.48 ± 68.16 | |
| | 42.0 ± 27.7 | 43.93 ± 32.49 | 37.4 ± 8.77 | |
Data were presented as mean ± standard deviation or number (%). Abbreviation: CRRT, Continuous renal replacement therapy, SBP Systolic blood pressure, DBP Diastolic blood pressure, MAP Mean arterial pressure, eGFR Estimated glomerular filtration rate, PT-INR Prothrombin time-international normalized ratio
Comparisons of fluid balance between survivors and non-survivors
| 14-day survival | ||||
|---|---|---|---|---|
| Overall | Survivor, | Non-survivor, | ||
| 24-h input, L | 3.0 ± 2.3 | 3.2 ± 2.6 | 2.7 ± 1.2 | 0.31 |
| 24-h output, L | 1.6 ± 2.1 | 1.9 ± 2.4 | 1.0 ± 1.1 | 0.05 |
| 48-h input, L | 2.7 ± 1.4 | 2.8 ± 1.4 | 2.5 ± 1.1 | 0.25 |
| 48- hr output, L | 1.8 ± 1.3 | 2.1 ± 1.3 | 1.0 ± 1.0 | < 0.001 |
| 72-h input, L | 2.6 ± 1.0 | 2.7 ± 1.1 | 2.3 ± 0.8 | 0.16 |
| 72-h output, L | 2.2 ± 1.5 | 2.5 ± 1.5 | 1.2 ± 0.9 | < 0.001 |
| Cumulative input on 3 day, L | 7.1 ± 4.7 | 7.8 ± 5.1 | 5.6 ± 2.9 | 0.02 |
| Cumulative output on 3 day, L | 4.7 ± 4.3 | 5.7 ± 4.5 | 2.3 ± 2.5 | < 0.001 |
| CFB on 3 day, L | 2.5 ± 4.1 | 2.1 ± 4.4 | 3.3 ± 3.3 | 0.17 |
| Cumulative input on 7 day, L* | 11.1 ± 8.7 | 12.2 ± 9.2 | 8.3 ± 6.6 | 0.04 |
| Cumulative output on 7 day, L* | 7.9 ± 7.4 | 9.3 ± 7.6 | 4.4 ± 5.3 | < 0.001 |
| CFB on 7 day, L* | 3.1 ± 5.8 | 2.8 ± 5.6 | 4.7 ± 6.3 | 0.21 |
Data were presented as mean ± standard deviation
Subcohort who survived 7 days or more (n = 86)
Abbreviation: Cumulative fluid balance
The associations between clinical parameters and 7-, 14-day mortalities
| 7-day mortality | 14-day mortality | |||||
|---|---|---|---|---|---|---|
| Variable | HR | 95% CI | HR | 95% CI | ||
| Age (per 1 year) | 1.00 | 0.97—1.04 | 0.93 | 1.00 | 0.97—1.03 | 0.82 |
| sex (male) | 0.73 | 0.32—1.64 | 0.45 | 0.84 | 0.42 -1.68 | 0.61 |
| Comorbidities | ||||||
| Diabetes mellitus | 0.45 | 0.20—1.02 | 0.05 | 0.50 | 0.25—0.98 | 0.04 |
| Hypertension | 0.43 | 0.19—0.97 | 0.04 | 0.57 | 0.28—1.14 | 0.11 |
| Cardiovascular disease | 0.55 | 0.23—1.32 | 0.18 | 0.70 | 0.35—1.42 | 0.33 |
| Malignancy | 0.73 | 0.27—1.96 | 0.55 | 0.91 | 0.37—2.19 | 0.82 |
| Sepsis | 1.69 | 0.58—4.94 | 0.31 | 1.63 | 0.67—3.93 | 0.28 |
| Vasopressor use | 1.96 | 0.84—4.58 | 0.12 | 2.45 | 1.17—5.12 | 0.02 |
| GCS | 0.82 | 0.73—0.93 | < 0.001 | 0.87 | 0.79—0.96 | < 0.001 |
| APACHE II | 1.08 | 1.02—1.15 | 0.01 | 1.07 | 1.02—1.12 | 0.01 |
| Prescription of CRRT | ||||||
| Duration of CRRT | 0.53 | 0.38—0.74 | < 0.001 | 0.90 | 0.82—0.99 | 0.04 |
| Fluid removal rate (mL/hr) | 0.99 | 0.98—1.00 | 0.06 | 0.99 | 0.98—1.00 | 0.06 |
| Use of anticoagulation | 1.81 | 0.80—4.07 | 0.15 | 0.40 | 0.20—0.81 | 0.01 |
Abbreviation: HR Hazard ratio, CI Confidence interval, CFB Cumulative fluid balance, APCHE II Acute Physiology and Chronic Health Evaluation II, GCS Glasgow Coma Scale
The associations between fluid balance and 7-,14-day mortalities
| 7-day mortality | 14-day mortality | |||||
|---|---|---|---|---|---|---|
| Variables* | HR | 95% CI | HR | 95% CI | ||
| 24 h input | 0.67 | 0.32—1.40 | 0.29 | 0.94 | 0.67—1.32 | 0.72 |
| 24 h output | 0.61 | 0.31- 1.19 | 0.15 | 0.73 | 0.40—1.33 | 0.31 |
| 48 h input | 1.06 | 0.70—1.60 | 0.79 | 0.83 | 0.45—1.55 | 0.56 |
| 48 h output | 0.28 | 0.12—0.70 | 0.01 | 0.67 | 0.38—1.19 | 0.17 |
| 72 h input | 0.26 | 0.08—0.88 | 0.03 | 0.88 | 0.44—1.75 | 0.71 |
| 72 h output | 0.34 | 0.13—0.85 | 0.02 | 0.44 | 0.23—0.86 | 0.02 |
| Cumulative input on 3 day | 0.72 | 0.61—0.86 | 0.01 | 1.01 | 0.89—1.14 | 0.92 |
| Cumulative output on 3 day | 0.65 | 0.41—0.90 | 0.01 | 0.77 | 0.64—0.93 | 0.01 |
| CFB on 3 day | 1.08 | 0.96—1.21 | 0.21 | 1.07 | 0.96—1.20 | 0.24 |
| Cumulative input on 7 day† | 1.04 | 0.99—1.09 | 0.15 | |||
| Cumulative output on 7 day† | 1.01 | 0.94—1.09 | 0.79 | |||
| CFB on 7 day† | 1.08 | 0.98—1.18 | 0.11 | |||
*Per 1L increase
† Subcohort who survived 7 days or more (n = 86)
Abbreviation: HR, Hazard ratio, CI Confidence interval, CFB Cumulative fluid balance
The adjusted hazard ratio of cumulative input and output for 7-, 14-day mortalities
| 7-day mortality | 14-day mortality | |||||||
|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 1 | Model 2 | |||||
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
Cumulative input on 3 day | 0.96 (0.79—1.17) | 0.71 | 0.85 (0.68—1.06) | 0.53 | 1.01 (0.90—1.13) | 0.92 | 0.98 (0.75—1.03) | 0.78 |
| Cumulative output on 3 day | 0.67 (0.48—0.93) | 0.01 | 0.66 (0.47—0.93) | 0.04 | 0.78 (0.64—0.94) | 0.01 | 0.79 (0.65—0.98) | 0.03 |
| Model 1 | Model 2 | |||||||
| HR (95% CI) | HR (95% CI) | |||||||
Cumulative input on 7 day† | 1.05 (0.97—1.14) | 0.20 | 1.03 (0.94—1.13) | 0.50 | ||||
| Cumulative output on 7 day† | 0.84 (0.79—1.02) | 0.09 | 0.91 (0.80—1.03) | 0.14 | ||||
*per 1.0 L increase
† Subcohort who survived 7 days or more (n = 86)
Model 1: Adjusted for age, sex, history of diabetes and hypertension
Model 2: Adjusted for age, sex, history of diabetes and hypertension, use of vasopressor, Glasgow Coma Scale, Acute Physiology and Chronic Health Evaluation II scale, and duration of CRRT
Abbreviation: HR Hazard ratio, CI Confidence interval
The comparisons of 7-, 14-day mortalities associated with cumulative input/output by median split
| 7-day mortality | 14-day mortality | |||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
High cumulative input on 3 day (vs. low cumulative input) | 0.81 (0.24—0.97) | 0.04 | 1.25 (0.55—3.05) | 0.67 |
High cumulative output on 3 day (vs. low cumulative output) | 0.18 (0.04—0.85) | 0.03 | 0.35 (0.14—0.89) | 0.02 |
High cumulative input on 7 day (vs. low cumulative input) | 1.30 (0.48—3.53) | 0.60 | ||
High cumulative output on 7 day (vs. low cumulative output) | 0.75 (0.29—1.94) | 0.55 | ||
Abbreviation: HR Hazard ratio, CI, Confidence interval
The association between low cumulative input/output and high input/output for 7-,14-day mortality risks
| 7- day mortality | 14-day mortality | |||||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | HR (95% CI) | HR (95% CI) | |||||
| Cumulative fluid on 3 day | Low output | High output | Low output | High output | ||||
| Low input | Reference | 0.31 (0.35—2.74) | 0.30 | Reference | 0.72 (0.17—3.00) | 0.64 | ||
| High input | 1.49 (0.37—5.68) | 0.56 | 0.16 (0.02—1.45) | 0.10 | 2.49 (0.81—7.63) | 0.11 | 0.50 (0.13—1.85) | 0.30 |
Abbreviation: HR Hazard ratio, CI Confidence interval